Background Aim of our study was to assess the load of bone disease at starting and during Ra-223 treatment as an overall survival (OS) predictor in metastatic castration-resistant prostate cancer (mCRPC) patients. Bone scan index (BSI) is defined as the percentage of total amount of bone metastasis on whole-body scintigraphic images. We present a specific software (DASciS) developed by an engineering team of "Sapienza" University of Rome for BSI calculation. Patients and methods 127 mCRPC patients bone scan images were processed with DASciS software, and BSI was tested as OS predictor. Results 546 bone scans were analyzed revealing that the extension of disease is a predictor of OS (0-3% = 28 months of median survival (MoMS]; 3%-5% = 11 MoMS, > 5% = 5 MoMS). BSI has been analyzed as a single parameter for OS, determining an 88% AUC. Moreover, the composition between the BSI and the 3-PS (3-variable prognostic score) determines a remarkable improvement of the AUC (91%), defining these two parameters as the best OS predictors. Conclusions This study suggests that OS is inversely correlated with the load of bone disease in mCRPC Ra-223-treated subjects. DASciS software appears a promising tool in identifying mCRPC patients that more likely take advantage from Ra-223 treatment. BSI is proposed as a predictive variable for OS and included to a multidimensional clinical evaluation permits to approach the patients' enrollment in a rational way, allowing to enhance the treatment effectiveness together with cost optimization.

Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment / Frantellizzi, Viviana; Pani, Arianna; Ippoliti, Maria Dea; Farcomeni, Alessio; Aloise, Irvin; Colosi, Mirco; Polito, Claudia; Pani, Roberto; Vincentis, Giuseppe De. - In: RADIOLOGY AND ONCOLOGY. - ISSN 1581-3207. - 54:1(2020), pp. 40-47. [10.2478/raon-2019-0058]

Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment

Frantellizzi, Viviana
Primo
;
Ippoliti, Maria Dea;Farcomeni, Alessio;Aloise, Irvin;Colosi, Mirco;Polito, Claudia;Pani, Roberto
Penultimo
;
Vincentis, Giuseppe De
Ultimo
2020

Abstract

Background Aim of our study was to assess the load of bone disease at starting and during Ra-223 treatment as an overall survival (OS) predictor in metastatic castration-resistant prostate cancer (mCRPC) patients. Bone scan index (BSI) is defined as the percentage of total amount of bone metastasis on whole-body scintigraphic images. We present a specific software (DASciS) developed by an engineering team of "Sapienza" University of Rome for BSI calculation. Patients and methods 127 mCRPC patients bone scan images were processed with DASciS software, and BSI was tested as OS predictor. Results 546 bone scans were analyzed revealing that the extension of disease is a predictor of OS (0-3% = 28 months of median survival (MoMS]; 3%-5% = 11 MoMS, > 5% = 5 MoMS). BSI has been analyzed as a single parameter for OS, determining an 88% AUC. Moreover, the composition between the BSI and the 3-PS (3-variable prognostic score) determines a remarkable improvement of the AUC (91%), defining these two parameters as the best OS predictors. Conclusions This study suggests that OS is inversely correlated with the load of bone disease in mCRPC Ra-223-treated subjects. DASciS software appears a promising tool in identifying mCRPC patients that more likely take advantage from Ra-223 treatment. BSI is proposed as a predictive variable for OS and included to a multidimensional clinical evaluation permits to approach the patients' enrollment in a rational way, allowing to enhance the treatment effectiveness together with cost optimization.
2020
DASciS software; bone disease; bone scan index; mCRPC; overall survival; radium223 dichloride
01 Pubblicazione su rivista::01a Articolo in rivista
Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment / Frantellizzi, Viviana; Pani, Arianna; Ippoliti, Maria Dea; Farcomeni, Alessio; Aloise, Irvin; Colosi, Mirco; Polito, Claudia; Pani, Roberto; Vincentis, Giuseppe De. - In: RADIOLOGY AND ONCOLOGY. - ISSN 1581-3207. - 54:1(2020), pp. 40-47. [10.2478/raon-2019-0058]
File allegati a questo prodotto
File Dimensione Formato  
Frantellizzi_Scintigraphic_2019.pdf

accesso aperto

Note: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087429/
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 526.9 kB
Formato Adobe PDF
526.9 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1349577
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 9
social impact